Physician profile
Wayne D Green
NPI 1114906278
$1,053.06
in general payments reported to CMS, 2019-2025
14 companies · $545 in 2025
The $545 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.64 · 2020: $11.67 · 2021: $115 · 2022: $24.72 · 2023: $93.04 · 2024: $209 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $248.31 | 2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $226.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $116.84 | 2024 | Voquezna |
| Abbvie INC. | $107.07 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.05 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $82.65 | 2020-2025 | Gattex |
| Redhill Biopharma INC. | $39.86 | 2021-2022 | |
| Endogastric Solutions, INC | $34.00 | 2023 | Esophyx |
| Boston Scientific Corporation | $27.86 | 2019 | |
| Novo Nordisk INC | $21.51 | 2025 | Wegovy |
| Celgene Corporation | $17.23 | 2023 | Zeposia |
| Lilly USA, LLC | $17.16 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $13.91 | 2023 | |
| Allergan, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.